Penetration of ampicillin and sulbactam in the lower airways during respiratory infections
| Autor: | Marie Rosseel, M E Van der Straeten, M. G. Bogaert, R.A. Pauwels, Y. Valcke |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
medicine.medical_specialty Exacerbation Gastroenterology Pharmacokinetics Ampicillin Internal medicine polycyclic compounds medicine Humans Urea Pharmacology (medical) Lung Diseases Obstructive Respiratory Tract Infections Aged Pharmacology Respiratory tract infections medicine.diagnostic_test business.industry digestive oral and skin physiology Respiratory disease Bacterial pneumonia Sulbactam biochemical phenomena metabolism and nutrition medicine.disease Infectious Diseases Bronchoalveolar lavage Immunology Female business Bronchoalveolar Lavage Fluid Research Article medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 34:958-962 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.34.6.958 |
| Popis: | We studied the penetration of ampicillin-sulbactam in the alveolar lining fluid (ALF) of eight patients after intravenous administration of 2,000 mg of ampicillin and 1,000 mg of sulbactam three times daily over 30 min. Bronchoalveolar lavage was performed on day 3, 30 min after the end of the morning drug administration. The mean penetration ratios (i.e., the ratios of the concentrations in ALF versus those in serum) were 53% (standard error, 12%) and 61% (standard error 31%) for ampicillin and sulbactam, respectively. The concentration ratio of ampicillin versus sulbactam in serum was not significantly different from that in ALF. From a pharmacokinetic point of view, ampicillin-sulbactam is a good choice for treatment of infectious exacerbation of chronic obstructive pulmonary disease and community-acquired bacterial pneumonia, since the concentrations of both drugs in ALF exceed the MICs for the respiratory pathogens responsible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|